Recursion Pharmaceuticals is trading 5% up at $3.35 as investors position themselves ahead of the company's second-quarter results scheduled for August 5, 2026.
- The stock is benefiting from a broader rally in the biotech sector and increased risk appetite across equity markets.
- With no major company-specific announcements reported, the price action appears driven by pre-earnings positioning and sector-wide momentum.